Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment

Molecular Diagnosis and Therapy

Volumn 13, Issue 1, 2009, Pages 31-47

  Zubek, Valentina Bayer ^a   Konski, Andre ^b  

^a Aureon Laboratories Inc   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANALYTICAL EQUIPMENT; ARTICLE; CANCER ADJUVANT THERAPY; COST EFFECTIVENESS ANALYSIS; HIGH RISK PATIENT; HUMAN; IMMUNOFLUORESCENCE; KATTAN POSTOPERATIVE NOMOGRAM; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MORPHOMETRICS; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; RECURRENCE RISK; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; WATCHFUL WAITING;

EID: 64349089746     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256313     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008 Mar-Apr; 58 (2): 71-96
2. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005 Aug 13-19; 366 (9485): 572-8
3. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006 Jun; 7 (6): 472-9
4. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004 Mar; 171 (3): 1141-7
5. Thompson IM, Tangen CM, Paradelo J. Adjuvant radiotherapy for patholo- gically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296 (19): 2329-35
6. Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95) [abstract no. 4513]. J Clin Oncol 2005 Jun; 23 (16S Pt I of II): 381
7. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001 Jun; 86 (6): 2787-91
8. Townsend MF, Sanders WH, Northway RO, et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997 Feb 1; 79 (3): 545-50
9. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999 Apr; 161 (4): 1219-22
10. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001 Nov; 166(5): 1724-8
11. Hornberger J, Cosier LE, Lyman GH. Economic analysis of targeting chemo- therapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005 May; 11 (5): 313-24
12. Shariat SF, Karakiewicz PI, Roehrborn CG, et al. An updated catalog of prostate cancer predictive tools. Cancer 2008 Dec 1; 113(11): 3075-99
13. Cordon-Cardo C, Kotsianti A, Verbel D, et al. Improved prediction of pro- state cancer recurrence through systems pathology. J Clin Invest 2007; 117 (7): 1876-83
14. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999 May; 17 (5): 1499-507
15. Graefen M, Karakiewicz PI, Cagiannos I, et al. Validation study of the accu- racy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002 Feb 15; 20 (4): 951-6
16. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005 Oct 1; 23 (28): 7005-12
17. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998 Apr; 13 (4): 397-409
18. Konski A, Watkins-Bruner D, Feigenberg S, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2006 Oct 1; 66 (2): 408-15
19. Piper NY, Kusada L, Lance R, et al. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis 2002; 5 (2): 164-6
20. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003 Jan; 41 (1): 153-64
21. Shipley WU, Lu JD, Pilepich MV, et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002 Dec 1; 54 (5): 1302-10
22. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004 Mar 17; 291(11): 1325-32
23. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998 Dec; 160 (6 Pt 2): 2428-34
24. Berge V, Thompson T, Blackman D. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting. Scand J Urol Nephrol 2007; 41 (3): 198-203
25. Grossfeld GD, Li YP, Lubeck DP, et al. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 2002 Aug; 168 (2): 530-5
26. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 1993 May 26; 269 (20): 2650-8
27. Konski A, Watkins-Bruner D, Brereton H, et al. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 2006 Jan 1; 106 (1): 51-7
28. Konski A, Sherman E, Krahn M, et al. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys 2005 Nov 1; 63 (3): 788-94
29. Scher HI, Kelly WM, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 1999 Feb 3; 91 (3): 244-51
30. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, Weinstein M, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 1991: 172-214
31. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985 Sum; 5(2): 157-77
32. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold M, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. Vol. 1. New York: Oxford University Press, 1996: 214-35
33. PDR Staff. 2006 Red Book: pharmacy's fundamental reference (Red Book drug topics). Montvale (NJ): Thomson PDR, 2006
34. EuroQol. A new facility for the measurement of health-related quality of life: the EuroQol Group. Health Policy 1990; 16: 199-208
35. Tufts-New England Medical Center Institute for Clinical Research and Health Policy Studies. Preference weights 1998-2001 [online]. Available from URL: http://www.tufts-nemc.org/cearegistry/data/docs/phaseIIpreferenceweights. pdf [Accessed 2007 Mar 5]
36. Kuntz K, Weinstein M. Modelling in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001: 141-71
37. Mehta SS, Lubeck DP, Sadetsky N, et al. Patterns of secondary cancer treat- ment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 2004 Jan; 171 (1): 215-9
38. Pass T, Goldstein L. A computerized aid for medical cost-effective analysis [abstract]. Med Decis Making 1981; 1: 465
39. Abramowitz MC, Pollack A. Postprostatectomy radiation therapy for prostate cancer. Semin Radiation Ocol 2008; 18 (1): 15-22
40. Current Controlled Trials. Radiotherapy and androgen deprivation in com- bination after local surgery [ISRCTN40814031; online]. Available from URL: http://www.controlled-trials.com/ISRCTN40814031/40814031 [Accessed 2009 Feb 9]
41. Svateck RS, Lee JJ, Roehrborn CG, et al. The cost of prostate cancer chemo- prevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev 2006; 15(8): 1485-9
42. Calvert NW, Morgan AB, Catto JW, et al. Effectiveness and cost- effectiveness of prognostic markers in prostate cancer. Br J Cancer 2003; 88 (1): 31-5
43. Moeremans K, Caekelbergh K, Annemans L. Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer. Value Health 2004; 7 (4): 472-81
44. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen sup- pression therapies in advanced prostate cancer. J Natl Cancer Inst 2000; 92(21): 1731-9
45. Ramsey S, Veenstra D, Clarke L, et al. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 2005; 66 (4): 835-9
46. Harrell Jr FE, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA 1982; 247 (18): 2543-6